1. Home
  2. SKYE vs OSUR Comparison

SKYE vs OSUR Comparison

Compare SKYE & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • OSUR
  • Stock Information
  • Founded
  • SKYE 2012
  • OSUR 2000
  • Country
  • SKYE United States
  • OSUR United States
  • Employees
  • SKYE N/A
  • OSUR N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • OSUR Medical/Dental Instruments
  • Sector
  • SKYE Health Care
  • OSUR Health Care
  • Exchange
  • SKYE Nasdaq
  • OSUR Nasdaq
  • Market Cap
  • SKYE 176.8M
  • OSUR 290.7M
  • IPO Year
  • SKYE N/A
  • OSUR 1986
  • Fundamental
  • Price
  • SKYE $6.06
  • OSUR $4.33
  • Analyst Decision
  • SKYE Strong Buy
  • OSUR Buy
  • Analyst Count
  • SKYE 4
  • OSUR 3
  • Target Price
  • SKYE $19.25
  • OSUR $6.50
  • AVG Volume (30 Days)
  • SKYE 324.8K
  • OSUR 977.8K
  • Earning Date
  • SKYE 01-01-0001
  • OSUR 08-06-2024
  • Dividend Yield
  • SKYE N/A
  • OSUR N/A
  • EPS Growth
  • SKYE N/A
  • OSUR N/A
  • EPS
  • SKYE N/A
  • OSUR 0.30
  • Revenue
  • SKYE N/A
  • OSUR $304,641,000.00
  • Revenue This Year
  • SKYE N/A
  • OSUR N/A
  • Revenue Next Year
  • SKYE N/A
  • OSUR N/A
  • P/E Ratio
  • SKYE N/A
  • OSUR $14.40
  • Revenue Growth
  • SKYE N/A
  • OSUR N/A
  • 52 Week Low
  • SKYE $1.44
  • OSUR $3.92
  • 52 Week High
  • SKYE $19.41
  • OSUR $8.45
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 36.48
  • OSUR 48.88
  • Support Level
  • SKYE $5.77
  • OSUR $4.15
  • Resistance Level
  • SKYE $6.83
  • OSUR $4.62
  • Average True Range (ATR)
  • SKYE 0.73
  • OSUR 0.15
  • MACD
  • SKYE 0.12
  • OSUR 0.04
  • Stochastic Oscillator
  • SKYE 34.47
  • OSUR 58.57

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About OSUR OraSure Technologies Inc.

OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.

Share on Social Networks: